Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Viral Infections

Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection

Bone Marrow Transplantation volume 27, pages 301–306 (2001)Cite this article

Abstract

Potential risk factors for CMV infection and the use of quantitative CMV PCR screening to guide pre-emptive anti-CMV therapy were reviewed retrospectively in 32 allogeneic bone marrow transplant patients accrued over a 2-year period. Significant CMV PCR positivity (an indicator of CMV infection) developed in 34% of patients. When analysed by recipient CMV IgG serostatus, 69% of seropositive recipients developed significant CMV PCR positivity while none of the seronegative recipients did so (P = 0.00007). Considering only the seropositive recipients, 100% of those who received the low intensity campath-1H/fludarabine/melphalan ‘mini-allograft’ conditioning regimen developed significant CMV PCR positivity, while only 44% of those who had received cyclophosphamide/TBI did so (P = 0.0337). The mean time to first episode of significant CMV PCR positivity for those who had received campath/fludarabine/ melphalan was 25 days while for those who had received cyclophosphamide/TBI, this was 66 days (P = 0.0372). For the first episode of significant CMV PCR positivity, the mean index and peak CMV PCR counts for those who had received campath/fludarabine/melphalan were 4.54 and 5.22 log copies/ml respectively, while for cyclophosphamide/TBI, the corresponding figures were 3.85 and 4.12 log copies/ml respectively (P = 0.2986 and P = 0.0472 for index and peak values). 85% of those who had significant CMV PCR positivity with the campath/fludarabine/melphalan regimen developed more than one such episode, while 50% of those receiving cyclophosphamide/TBI regimen did so (P = 0.491). Significant CMV PCR positivity was associated with symptoms in a proportion of patients (pyrexia 45%, cough 18%, rise in AST 72%). No patient developed overt CMV disease. CMV PCR is useful for guiding pre-emptive anti-CMV therapy and for monitoring response. Bone Marrow Transplantation (2001) 27, 301–306.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Nguyen Q, Champlin R, Giralt S et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients Clin Infect Dis 1999 28: 618–623

    Article  CAS  Google Scholar 

  2. Noble S, Faulds D . Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients Drugs 1998 56: 115–146

    Article  CAS  Google Scholar 

  3. Stocchi R, Ward KN, Fanin R et al. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation Haematologica 1999 84: 71–79

    CAS  PubMed  Google Scholar 

  4. Prentice HG, Kho P . Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant Bone Marrow Transplant 1997 19: 135–142

    Article  CAS  Google Scholar 

  5. Milpied N . Prophylaxis of cytomegalovirus infection in bone marrow transplant patients Int J Antimicrobial Agents 1996 7: 277–281

    Article  CAS  Google Scholar 

  6. Tsinontides AC, Bechtel TP . Cytomegalovirus prophylaxis and treatment following bone marrow transplantation Ann Pharmacother 1996 30: 1277–1290

    Article  CAS  Google Scholar 

  7. Zaia JA, Forman SJ . Cytomegalovirus infection in the bone marrow transplant recipient Infect Dis Clin North Am 1995 9: 879–900

    CAS  PubMed  Google Scholar 

  8. Griffiths PD . Prophylaxis against CMV infection in transplant patients J Antimicrob Chemother 1997 39: 299–301

    Article  CAS  Google Scholar 

  9. Salzberger B, Bowden RA, Hackman RC . Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for the prevention of cytomegalovirus disease: risk factors and outcome Blood 1997 90: 2502–2508

    CAS  PubMed  Google Scholar 

  10. Carella AM, Camplin R, Slavin S et al. Mini-allografts: ongoing trials in humans Bone Marrow Transplant 2000 25: 345–350

    Article  CAS  Google Scholar 

  11. Guiver M, Fox AJ, Mutton K et al. Comparative evaluation of CMV viral load using Taqman quantitative CMV PCR and comparison with CMV antigenaemia in heart and lung transplants Transplantation (in press)

  12. Keating MJ, O'Brien S, Lerner S et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy Blood 1998 92: 1165–1171

    CAS  PubMed  Google Scholar 

  13. Osterborg A, Fassas AS, Anagnostopoulos A et al. Humanized CD52 monoclonal antibody Campath-1H as first line treatment in chronic lymphocytic leukaemia Br J Haematol 1996 93: 151–153

    Article  CAS  Google Scholar 

  14. Grigg A, Chapman R, Szer J . Fatal CMV pneumonia associated with steroid therapy after autologous transplantation in patients previously treated with fludarabine Bone Marrow Transplant 1998 21: 619–621

    Article  CAS  Google Scholar 

  15. Bowen AL, Zomas A, Emmett E et al. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia Br J Haematol 1997 96: 617–619

    Article  CAS  Google Scholar 

  16. Manteiga R, Martino R, Sureda A et al. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience Bone Marrow Transplant 1998 22: 899–904

    Article  CAS  Google Scholar 

  17. Koehler M, St George K, Ehrlich GD et al. Prevention of CMV disease in allogeneic BMT recipients by cytomegalovirus antigenemia-guided preemptive ganciclovir therapy J Pediatr Hematol Oncol 1997 19: 43–47

    Article  CAS  Google Scholar 

  18. Humar A, O'Rourke K, Lipton J et al. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation Bone Marrow Transplant 1999 23: 45–51

    Article  CAS  Google Scholar 

  19. Egan JJ, Barber L, Lomax J et al. Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients Thorax 1995 50: 9–13

    Article  CAS  Google Scholar 

  20. Ljungman P, Aschan J, Lewensohn-Fuchs I et al. Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients Transplantation 1998 66: 1330–1334

    Article  CAS  Google Scholar 

  21. Boeckh M, Gallez-Hawkins GM, Myerson D et al. Plasma polymerase chain reaction for cytomegalovirus DNA after allogeneic marrow transplantation: comparison with polymerase chain reaction using peripheral blood leukocytes, pp65 antigenemia, and viral culture Transplantation 1997 64: 108–113

    Article  CAS  Google Scholar 

  22. Matsunaga T, Sakamaki S, Ishigaki S et al. Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients Int J Hematol 1999 69: 105–111

    CAS  PubMed  Google Scholar 

  23. Kanda Y, Chiba S, Suzuki T et al. Time course analysis of semi-quantitative PCR and antigenaemia assay for prevention of cytomegalovirus disease after bone marrow transplantation Br J Haematol 1998 100: 222–225

    Article  CAS  Google Scholar 

  24. Emery VC, Sabin CA, Cope AV et al. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation Lancet 2000 355: 2032–2036

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the staff on the Acute Leukaemia Unit at the Christie Hospital for their assistance during this study.

Author information

Authors and Affiliations

  1. Public Health Laboratory, Withington Hospital, Manchester, UK

    AO Qamruddin, BA Oppenheim, M Guiver & KJ Mutton

  2. Department of Haematological Oncology, Christie Hospital, Manchester, UK

    R Chopra

Authors
  1. AO Qamruddin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. BA Oppenheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Guiver
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. KJ Mutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R Chopra
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Qamruddin, A., Oppenheim, B., Guiver, M. et al. Screening for cytomegalovirus (CMV) infection in allogeneic bone marrow transplantation using a quantitative whole blood polymerase chain reaction (PCR) method: analysis of potential risk factors for CMV infection. Bone Marrow Transplant 27, 301–306 (2001). https://doi.org/10.1038/sj.bmt.1702778

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702778

Keywords

This article is cited by

Search

Advanced search

Quick links